Atara Biotherapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
ATRA$8.10-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except per share amounts)
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended September 30, · · Nine Months Ended September 30, | ||||||||||||
| · · 2026 · · 2025 · · 2026 · · 2025 | ||||||||||||
| Commercialization revenue | | $1,224 | | $3,453 | | $2,370 | | $119,177 | ||||
| Costs and operating expenses: | | | | | | | | | | | | |
| Cost of commercialization revenue | | | 265 | | | 115 | | | 580 | | | 21,108 |
| Research and development expenses | | | 1,099 | | | 2,925 | | | 2,608 | | | 37,668 |
| General and administrative expenses | | | 2,830 | | | 3,987 | | | 10,241 | | | 21,976 |
| Total costs and operating expenses | | | 4,194 | | | 7,027 | | | 13,429 | | | 80,752 |
| Income (loss) from operations | | | (2,970) | | | (3,574) | | | (11,059) | | | 38,425 |
| Other income (expense), net: | | | | | | | | | | | | |
| Interest income | | | 68 | | | 204 | | | 199 | | | 583 |
| Interest income (expense) on sale of future revenues | | | 682 | | | (906) | | | (333) | | | (2,745) |
| Other income (expense), net | | | (9) | | | 1 | | | (14) | | | (138) |
| Total other income (expense), net | | | 741 | | | (701) | | | (148) | | | (2,300) |
| Income (loss) before provision for (benefit from) income taxes | | | (2,229) | | | (4,275) | | | (11,207) | | | 36,125 |
| Provision for (benefit from) income taxes | | | — | | | 28 | | | 1 | | | 31 |
| Net income (loss) | | $(2,229) | | $(4,303) | | $(11,208) | | $36,094 | ||||
| Other comprehensive gain (loss): | | | | | | | | | | | | |
| Unrealized gain (loss) on available-for-sale securities | | | 1 | | | 2 | | | (2) | | | (6) |
| Comprehensive income (loss) | | $(2,228) | | $(4,301) | | $(11,210) | | $36,088 | ||||
| | | | | | | | | | | | | |
| Basic (loss) earnings per common share | | $(0.15) | | $(0.32) | | $(0.76) | | $2.96 | ||||
| Diluted (loss) earnings per common share | | $(0.15) | | $(0.32) | | $(0.76) | | $2.93 | ||||
| | | | | | | | | | | | | |
| Basic and diluted weighted-average shares outstanding | | | 15,326 | | | 13,564 | | | 14,818 | | | 12,185 |
| Diluted weighted-average shares outstanding | | | 15,326 | | | 13,564 | | | 14,818 | | | 12,319 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.